Vault Bioventures

We want to take a moment to express how truly grateful we are for our families, friends, partners, and collaborators. Together, we’ve navigated challenges, celebrated successes, and created meaningful impact in ways that go beyond business. Thank you everyone for allowing us to be part of your journey. As we gather with our loved ones this season, know that you hold a special place in our thoughts and hearts. Wishing you and your families a warm, joyful, and fulfilling Thanksgiving. Here’s to many more shared experiences ahead! Sincerely, The Vault Team

MindMed has appointed Dr. Gregg Pratt as Chief Regulatory and Quality Assurance Officer, signaling its commitment to advancing MM120, its LSD-based therapy, through Phase III trials for mental health conditions. With over 30 years of experience in drug development and registration, Dr. Pratt’s expertise will be pivotal as MindMed navigates the regulatory landscape and prepares for potential commercialization. Insights and Impact ?? - Strategic Leadership: Dr. Pratt’s extensive background in psychiatry and neurology aligns perfectly with MindMed’s mission to revolutionize mental health treatment. - Regulatory Focus: His appointment strengthens MindMed’s capacity to meet rigorous regulatory standards, a critical step as MM120 progresses to Phase III trials. - Market Potential: MindMed’s efforts highlight growing industry interest in psychedelics as transformative mental health therapies. Questions to Consider ?? - How will MindMed leverage regulatory expertise to gain a competitive edge in the psychedelics space? - Could MM120’s success pave the way for wider acceptance and integration of psychedelic-based therapies? - What challenges lie ahead in scaling regulatory and quality processes for commercialization? #MindMed #PsychedelicTherapies #MentalHealthInnovation #DrugDevelopment #ClinicalTrials #RegulatoryAffairs #Neurology #Psychiatry #BiotechLeadership

GSK’s linerixibat has achieved positive Phase III results in the GLISTEN trial, offering hope for patients with primary biliary cholangitis (PBC) suffering from relentless itch (cholestatic pruritus). As a targeted IBAT inhibitor, linerixibat significantly reduced itch scores over 24 weeks compared to placebo, marking a potential breakthrough for this rare autoimmune liver disease. With limited options for managing PBC-associated pruritus, these findings could fill a critical gap in treatment. How might this advancement reshape care for PBC patients? Could targeted therapies like linerixibat become a blueprint for addressing other autoimmune conditions with unmet needs? #RareDisease #AutoimmuneDisorders #PBC #GSK #ClinicalTrials #TargetedTherapies #PharmaInnovation #PatientCare #IBATInhibitors #LiverHealth

Viking Therapeutics has bolstered its case for VK2809 as a leading contender in the metabolic dysfunction-associated steatohepatitis (MASH) market. Final phase 2b VOYAGE trial results showed significant reductions in liver fat content (37%-55%) and improved liver fibrosis scores (44%-57%) after 52 weeks, positioning VK2809 as a potential best-in-class oral therapy. Insights and Impact ?? - Efficacy & Safety: VK2809 demonstrated strong antifibrotic effects, even in an underpowered study, with a safety profile comparable to placebo—critical for long-term MASH treatment. - Market Opportunity: With FDA-approved Rezdiffra paving the way, VK2809 is poised to compete in a growing market addressing a historically challenging condition. - Scientific Recognition: Presenting as a late-breaker at AASLD underscores the importance of Viking’s progress in this space. Questions to Consider ?? - How will Viking’s VK2809 differentiate itself from Rezdiffra and other MASH contenders? - Could broader success in MASH drug development improve earlier diagnosis and intervention rates? - What impact might these advancements have on the overall management of liver diseases linked to metabolic dysfunction? #VikingTherapeutics #MASH #LiverHealth #DrugDevelopment #ClinicalTrials #MetabolicHealth #HealthcareInnovation #AntifibroticTherapies #Biotech

?? Metabolic Breakthroughs: From Weight Loss to Liver Health, this week's top metabolic research is packed with developments! ?? ADvantage Therapeutics Inc. launches Klothea Bio, pioneering Klotho protein therapies for age-related disease prevention Viking Therapeutics, Inc. shows promising results for VK2809 in treating NASH/MASH, significantly reducing liver fat Eli Lilly and Company partners with Laekna Therapeutics to develop innovative obesity treatment targeting lean mass New insights: ?? Semaglutide demonstrates remarkable liver benefits ?? Scientists uncover liver-brain communication pathways ?? Probiotics show potential in mitigating toxic chemical exposure This week's research is reshaping our understanding of metabolic health, offering hope for more effective treatments in obesity, liver disease, and age-related conditions. #Metabolic #Research #Healthcare #Innovation #Biotechnology Want the full scoop? Check out the latest Metabolic News Weekly! ??

Canvas Medical is breaking new ground with Anova?, the first EMR platform tailored to longevity medicine. As the demand for personalized, proactive care grows, Anova equips clinicians with tools to address aging-related conditions and optimize health outcomes—all while simplifying practice management. Insights and Impact ?? - Tailored for Longevity: Anova offers evidence-based protocols, from GLP-1 therapies to lifestyle strategies, empowering clinicians to deliver cutting-edge care in a rapidly growing field. - Seamless Integration: Features like wearable data integration, e-prescribing, and membership management streamline workflows, enhancing both patient experience and operational efficiency. - Driving Innovation: By addressing gaps in fragmented healthcare systems, Canvas Medical positions itself as a pioneer in the longevity market, projected to grow at 5.2% CAGR. Questions to Consider ?? - How will Anova shape the future of longevity medicine by aligning technology with personalized care? - Could similar platforms revolutionize other specialized fields of medicine? - What challenges might arise as longevity medicine scales and integrates into broader healthcare ecosystems? #LongevityMedicine #HealthTech #CanvasMedical #AnovaEMR #AgingWell #PersonalizedCare #DigitalHealth #HealthcareInnovation #PatientExperience

Novartis is stepping into the future of T cell therapy by partnering with Vyriad to develop in vivo CAR-T treatments using lentiviral vectors. This innovative approach programs T cells directly within the patient’s body, bypassing the complex ex vivo engineering process. If successful, it could significantly expand access to CAR-T therapies and address unmet medical needs in cancer treatment. With competitors like Umoja and Sana pursuing (or pivoting from) similar approaches, this collaboration highlights the race to innovate in vivo gene editing. How might this shift streamline CAR-T manufacturing and delivery? Could it become a transformative standard in cell therapy? #CellTherapy #CAR_T #InVivoTherapy #GeneEditing #BiotechInnovation #CancerResearch #Novartis #Vyriad #TCellTherapy #Biopharma

Amgen is welcoming Howard Chang, PhD, as its new Senior VP of Research and Chief Scientific Officer. A renowned expert in genome science and cancer biology, Chang brings decades of groundbreaking work to Amgen’s global R&D efforts, signaling a commitment to advancing innovation across rare diseases, oncology, inflammation, and cardiometabolic indications. Insights and Impact ?? - Visionary Leadership: Chang’s expertise in human genetics and genomic technologies positions Amgen to target complex disease biology with cutting-edge approaches. - Strategic Alignment: His role will unify Amgen’s global research priorities and drive impactful therapies in critical therapeutic areas. - R&D Evolution: With a high-tech focus, Chang’s leadership reflects Amgen’s ambition to remain at the forefront of biotech innovation. Questions to Consider ?? - How might Chang’s background in noncoding RNA and gene control influence Amgen’s research trajectory? - What opportunities will his leadership create for Amgen’s pipeline in underserved areas like rare diseases and advanced oncology? - Could Chang’s appointment accelerate the development of personalized medicine initiatives at Amgen? #Amgen #Leadership #BiotechInnovation #Genomics #RAndDLeadership #OncologyResearch #RareDiseases #HealthcareInnovation #HumanGenetics

TRexBio’s $84M Series B funding highlights the biotech’s growing momentum in the competitive immune drug space. With a focus on activating regulatory T cells (Tregs), TRex is advancing TRB-061, its candidate for atopic dermatitis and ulcerative colitis, into clinical trials while leveraging partnerships with industry giants like Eli Lilly and J&J. Insights and Impact ? - Innovative Approach - By targeting Tregs, TRex is exploring a novel pathway in immune regulation, potentially offering new treatment options for autoimmune diseases.?? - Strategic Partnerships - Collaborations with Lilly and J&J validate TRex’s technology while providing critical funding and development milestones.?? - Growing Market - The immune drug sector remains lucrative, with billions in venture capital fueling innovations aimed at improving efficacy and safety.? Questions to Consider ? ?? - How will TRex’s Treg-focused approach differentiate its therapies from established options like TNF or JAK inhibitors??? - Could TRex’s partnerships with pharma giants accelerate the commercialization of its drug candidates??? - What does TRex’s success signal for the future of venture-backed immune drug development?? #BiotechNews #ImmuneTherapies #AutoimmuneResearch #TRexBio #DrugDevelopment #VentureCapital #PharmaInnovation #RegulatoryTCells #HealthcareInvestments

Cardinal Health is doubling down on its strategic focus with two major acquisitions: a $2.8 billion majority stake in GI Alliance (GIA) and a $1.1 billion purchase of Advanced Diabetes Supply Group (ADSG). These moves expand Cardinal’s reach into multispecialty GI care and at-home diabetes management, showcasing its commitment to enhancing patient-centric care while driving specialty and at-home solutions growth. With GIA’s robust network of over 900 physicians and ADSG’s ability to serve nearly 500,000 diabetes patients annually, these acquisitions align with Cardinal’s goal of delivering integrated, innovative solutions across the care continuum. How will this expanded portfolio shape Cardinal Health’s influence in specialty care? Can investments like these lead the way in bridging the gap between traditional and at-home healthcare?? #HealthcareInnovation #SpecialtyCare #AtHomeHealthcare #DiabetesCare #GIAlliance #CardinalHealth #PatientCentricity #MergersAndAcquisitions #HealthcareStrategy #ValueBasedCare